The company generated net product revenues of $194.8 million for the full year 2025 from global sales of IMCIVREE, compared to $130.1 million in 2024. The company has a supplemental New Drug Application (sNDA) under FDA review with a PDUFA goal date of March 20, 2026, and is also pursuing European Medicines Agency approval for setmelanotide in acquired hypothalamic obesity. The company is investing in next-generation MC4R agonist development, U.S. commercial support for the HO launch, and building operations in Japan.
Cyborg Score Rationale
IMCIVREE net product revenue grew approximately 50% year-over-year to $194.8 million in 2025, demonstrating strong commercial momentum. Net losses narrowed to $201.9 million in 2025 from $264.6 million in 2024, showing improving operational trajectory. The company maintains a strong cash position of approximately $388.9 million as of December 31, 2025, providing runway for pipeline advancement.
Top Insights
IMCIVREE revenue growth of 50% year-over-year was driven by approximately 10% increase in the number of patients on reimbursed therapy globally
Phase 3 TRANSCEND trial of setmelanotide showed -18.8% placebo-adjusted BMI reduction with mean BMI change of -16.4% on drug versus +2.4% on placebo
FDA confirmed bivamelagon (next-gen MC4R agonist) is ready for Phase 3, though the agency requires a full 12-month double-blind trial with ~142 patients; Phase 3 initiation expected by year-end 2026
International organization expanded to over 100 employees across 13 countries with IMCIVREE available in more than 25 countries outside the U.S.
Named Competitors
GLP-1 Receptor Agonists — Large obesity market competitor with Ozempic/Wegovy
GLP-1 Receptor Agonists — Mounjaro/Zepbound in obesity and diabetes